Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

5.20
+0.23004.63%
Pre-market: 5.450.2514+4.83%08:01 EDT
Volume:1.40M
Turnover:7.04M
Market Cap:592.80M
PE:-3.58
High:5.28
Open:4.89
Low:4.84
Close:4.97
52wk High:6.16
52wk Low:1.60
Shares:114.00M
Float Shares:102.00M
Volume Ratio:1.18
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4506
EPS(LYR):-1.2306
ROE:-37.26%
ROA:-17.24%
PB:2.45
PE(LYR):-4.23

Loading ...

Perspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results

Reuters
·
Jan 12

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data

TIPRANKS
·
Jan 09

Perspective Therapeutics Reports Positive Interim Results for [212Pb]VMT-α-NET in Neuroendocrine Tumor Trial

Reuters
·
Jan 09

Perspective Therapeutics Presents Updated Interim Data of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial at the 2026 Asco Gastrointestinal Cancers Symposium

THOMSON REUTERS
·
Jan 09

Perspective Therapeutics Reports Promising [212Pb]VMT-α-NET Data in Neuroendocrine Tumor Trial

Reuters
·
Dec 04, 2025

Perspective Therapeutics (CATX) Receives a Buy from Roth MKM

TIPRANKS
·
Nov 28, 2025

Perspective Therapeutics (CATX) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 26, 2025

Perspective Therapeutics Inc : Truist Securities Assumes Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
Nov 24, 2025

Perspective Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Nov 22, 2025

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program

TIPRANKS
·
Nov 21, 2025

Perspective Therapeutics price target lowered to $7 from $18 at UBS

TIPRANKS
·
Nov 21, 2025

Perspective Therapeutics to Participate in Upcoming December Conferences

GlobeNewswire
·
Nov 20, 2025

Perspective Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Nov 19, 2025

B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating

MT Newswires Live
·
Nov 18, 2025

Perspective Therapeutics Chief Accounting Officer Jonathan Robert Hunt Acquires Common Shares

Reuters
·
Nov 17, 2025

Director Robert F. Williamson III Acquires Common Shares of Perspective Therapeutics Inc

Reuters
·
Nov 14, 2025

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 12, 2025

Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability

TIPRANKS
·
Nov 12, 2025

Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential

TIPRANKS
·
Nov 12, 2025

Wedbush Keeps Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 11, 2025